You may be able to predict potential heart failure events weeks in advance. Discover HeartLogic™ here: bddy.me/2UsGDBB
BostonSci Cardiology
9,680 posts
BostonSci Cardiology
@BSCCardiology
Boston Scientific Cardiology. We invite physicians in the U.S. to learn about our cardiology & electrophysiology therapies and devices. bit.ly/2cOqgdl
- We’re excited to announce that we’ve agreed to acquire @BaylisMedical. Their portfolio of left heart access solutions will support our efforts to improve procedural efficiencies with tools designed to make left atrial access safer and more predictable bit.ly/3DbgpIM $BSX
- Now published: Cost effectiveness of left atrial appendage closure with the WATCHMAN Device compared to warfarin for stroke risk reduction in NVAF patients with a prior stroke now published in the Stroke journal! #LAAC #LAA @American_Heart stroke.ahajournals.org/content/early/…
- The FARAPULSE™ Pulsed Field Ablation System is now FDA approved! FARAPULSE™ offers tissue selective cardiac #ablation for the treatment of PAF which minimizes thermal risk. See the FARAPULSE™ difference: bostonscientific.com/en-US/products… Safety info: bit.ly/47VaqXO
00:00 - The first-ever FARAFLEX™ Mapping and Pulsed Field Ablation (PFA) Catheter case was completed at KBC Split in Split, Croatia as part of the premarket ELEVATE-PF feasibility study performed by Dr. Anic and observed by Drs. Wazni and Saliba. Our innovation and clinical investment
00:00 - Watch how an electroanatomical map was able to be quickly created using the FARAWAVE™ NAV PFA Catheter using the flower and basket configurations on the FARVIEW™ Software Module, by Dr. Mike Manogue and the Mission Hospital team. This map assisted in the PVI ablation for a
00:00 - #Heartfailure rates are expected to increase by 46% by 2030. This case study featured in @EPLabDigest reviews how a multisensor heart failure diagnostic can reduce potential hospital readmissions due to #HF. bddy.me/34kUcaA IMPORTANT SAFETY INFO: bddy.me/34ePJWZ
- PRIMARY ENDPOINTS MET! We are excited to announce the positive results from OPTION Clinical Trial – the primary endpoints showed WATCHMAN FLX™ was equally effective to OACs, with a superior safety profile at 36 months, which allowed patients to eliminate continuous medication
- 1/ Today we want to celebrate the first US commercial cases using the FARAPULSE™ PFA System. To kick us off, congrats to Dr. @VivekReddyMD and the team at @MountSinaiHeart for being a part of this milestone and completing your first commercial FARAPULSE™ cases!
- We are excited to announce FDA approval for the WATCHMAN FLX™ Left Atrial Appendage Closure Device to reduce stroke risk for patients with non-valvular #AFib who need an alternative to oral anticoagulation: bit.ly/32H2LOQ #LAAC Safety info: bit.ly/32EJHAz
GIF - The next-level FARAPULSE™ mapping experience is here! The first FARAVIEW™ cases are officially beginning in the United States. We’re excited to provide physicians the next leap forward in mapping for the leading PFA system and to deliver confidence in PFA visualization. Learn
00:00